Wiley Publishes Review on Artificial Intelligence Transforming Drug Discovery and Development

Artificial Intelligence is identified as a central focus in a 2026 Wiley Online Library article titled “Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation,” authored by Ali and co‑authors. The paper reviews AI’s emerging role in creating new medicines and outlines key research directions.

Drug Discovery processes are examined for how AI technologies—including machine learning and deep learning—can streamline target identification, accelerate compound screening, and improve predictive modeling, as detailed in the authors’ analysis within the study.

Pharmaceutical Innovation is described as being reshaped by AI‑driven workflows, with the article suggesting possible influences on development timelines, cost structures, and the ability to design more personalized therapies within the drug pipeline.

The Publication appears in the peer‑reviewed journal Drug Development Research, offering researchers and industry professionals a comprehensive overview of AI applications across the drug development pipeline and highlighting future research priorities for the field.